Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIPNASDAQ:CALTNASDAQ:CKPTNASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$62.00-0.5%$66.93$52.50▼$77.00$1.35B0.56292,850 shs418,019 shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/ACKPTCheckpoint Therapeutics$4.15-0.2%$4.02$1.54▼$4.50$347.62M1.181.26 million shs866,682 shsSPRYARS Pharmaceuticals$13.35+0.5%$13.25$7.55▼$18.51$1.31B0.841.20 million shs1.44 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals-0.48%-11.77%-8.98%+3.89%-7.93%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%+83.66%CKPTCheckpoint Therapeutics-0.24%+0.12%+4.01%+23.88%+169.48%SPRYARS Pharmaceuticals+0.45%-4.78%-4.98%+14.79%+50.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIPANI Pharmaceuticals4.8548 of 5 stars4.53.00.03.33.93.31.3CALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/ACKPTCheckpoint Therapeutics2.1003 of 5 stars1.24.00.04.21.50.80.0SPRYARS Pharmaceuticals3.1914 of 5 stars3.62.00.00.03.14.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.00Buy$80.1329.23% UpsideCALTCalliditas Therapeutics AB (publ) 2.00Hold$39.25-1.88% DownsideCKPTCheckpoint Therapeutics 2.33Hold$4.334.42% UpsideSPRYARS Pharmaceuticals 3.17Buy$31.00132.21% UpsideCurrent Analyst Ratings BreakdownLatest CKPT, ANIP, SPRY, and CALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.004/21/2025ANIPANI PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$62.00 ➝ $65.004/11/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.003/31/2025CKPTCheckpoint TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.80 ➝ $4.803/17/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$94.00 ➝ $94.003/14/2025ANIPANI PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.003/12/2025ANIPANI PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$85.003/11/2025CKPTCheckpoint TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$4.103/10/2025CKPTCheckpoint TherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$7.00 ➝ $4.103/10/2025CKPTCheckpoint TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $4.803/7/2025SPRYARS PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$30.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$614.38M2.20$6.87 per share9.03$21.13 per share2.93CALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74CKPTCheckpoint Therapeutics$41K8,478.55N/AN/A($0.47) per share-8.83SPRYARS Pharmaceuticals$89.15M14.71N/AN/A$2.40 per share5.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals$18.78M-$1.27N/A14.73N/A-1.28%15.87%6.88%N/ACALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/ACKPTCheckpoint Therapeutics-$51.85M-$1.43N/A∞N/AN/AN/A-659.07%N/ASPRYARS Pharmaceuticals-$54.37M$0.08N/AN/AN/AN/A-22.56%-21.82%5/14/2025 (Estimated)Latest CKPT, ANIP, SPRY, and CALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SPRYARS Pharmaceuticals-$0.35N/AN/AN/A$7.48 millionN/A5/13/2025Q1 2025CKPTCheckpoint Therapeutics-$0.10-$0.19-$0.09-$0.19$4.53 millionN/A5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37$1.70+$0.33$0.69$179.75 million$197.12 million3/28/2025Q4 2024CKPTCheckpoint Therapeutics-$0.22-$0.69-$0.47-$0.69N/A$0.04 million3/20/2025Q4 2024SPRYARS Pharmaceuticals-$0.04$0.52+$0.56$0.52$15.46 million$86.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/ACKPTCheckpoint TherapeuticsN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.522.741.97CALTCalliditas Therapeutics AB (publ)9.442.692.59CKPTCheckpoint TherapeuticsN/A0.290.29SPRYARS PharmaceuticalsN/A12.5612.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%CALTCalliditas Therapeutics AB (publ)2.83%CKPTCheckpoint Therapeutics22.00%SPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals11.10%CALTCalliditas Therapeutics AB (publ)2.20%CKPTCheckpoint Therapeutics2.10%SPRYARS Pharmaceuticals40.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.77 million18.36 millionOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableCKPTCheckpoint Therapeutics1083.76 million47.81 millionOptionableSPRYARS Pharmaceuticals9098.21 million58.21 millionOptionableCKPT, ANIP, SPRY, and CALT HeadlinesRecent News About These CompaniesBalyasny Asset Management L.P. Purchases 322,423 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)May 14 at 4:21 AM | marketbeat.comARS Pharmaceuticals's Earnings: A PreviewMay 14 at 3:30 AM | benzinga.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Acquired by Voya Investment Management LLCMay 11 at 4:24 AM | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by DAFNA Capital Management LLCMay 10, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Deerfield Management Company L.P. Series CMay 10, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Ancora Advisors LLCMay 10, 2025 | marketbeat.comARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 KilogramsMay 7, 2025 | globenewswire.comAlyeska Investment Group L.P. Acquires 1,128,724 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)May 7, 2025 | marketbeat.comInvesco Ltd. Reduces Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)May 6, 2025 | marketbeat.comARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial ResultsMay 5, 2025 | globenewswire.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Marshall Wace LLPMay 5, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Holdings Lifted by Barclays PLCMay 5, 2025 | marketbeat.comARS Pharmaceuticals Partners with ALK for Neffy PromotionMay 3, 2025 | investing.comALK Abello inks neffy co-promotion deal in USAMay 3, 2025 | thepharmaletter.comARS Pharmaceuticals (SPRY) Expected to Announce Quarterly Earnings on ThursdayMay 3, 2025 | marketbeat.comARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffyMay 3, 2025 | msn.comARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. PediatriciansMay 2, 2025 | globenewswire.comTower Research Capital LLC TRC Has $481,000 Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)May 2, 2025 | marketbeat.comARS Pharmaceuticals Has A Blockbuster CandidateApril 30, 2025 | seekingalpha.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Buy" from AnalystsApril 28, 2025 | marketbeat.comRaymond James Financial Inc. Invests $6.58 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)April 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCKPT, ANIP, SPRY, and CALT Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$62.00 -0.30 (-0.48%) As of 05/13/2025 04:00 PM EasternANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Calliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 05/12/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Checkpoint Therapeutics NASDAQ:CKPT$4.15 -0.01 (-0.24%) As of 05/13/2025 04:00 PM EasternCheckpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.ARS Pharmaceuticals NASDAQ:SPRY$13.35 +0.06 (+0.45%) As of 05/13/2025 04:00 PM EasternARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Stock Surges on Bullish News: How High Could It Climb? NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner? Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long Why Boeing May Be Ready to Take Off After Latest Developments Goldman Sachs Warns of 20% Market Sell-Off: Are They Right? 3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest Loser Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
